12 / 14
Page 38
conferenceseries
.com
Volume 9
Journal of Clinical & Experimental Ophthalmology
World Ophthalmology 2018
July 10-11, 2018
July 10-11, 2018 Bangkok, Thailand
3
rd
International Conference on
Ophthalmology
Retrospective efficacy and safety analysis of Zybev (bio-similar of Bevacizumab) use at tertiary eye
care centers in India: Spectra study
Sandesh Warudkar
Cadila Healthcare Ltd, India
Purpose:
The purpose of this study was to evaluate the efficacy and safety profile of intra-vitreal injection of Bevacizumab bio-
similar (Zybev) for various retinal neovascular conditions.
Methods:
Retrospective analysis was carried out on 108 injections which were administered with intra-vitreal Zybev injection
at different tertiary eye care centers in India. The injections were administered for various indications such as wet Age-related
Macular Degeneration (AMD), Diabetic Macular Edema (DME) and Retinal Vein Occlusion (RVO).
Results:
The mean age of the patients was 62.7±8.40 years. A total of 61.1% injections were administered to men and 39.9% to
women. The indications for which the injection was administered were DME (43.6%), wet AMD (28.7 %) and RVO (27.7%).
Mean pretreatment BCVAwas 0.94±0.29 logMAR with CMT 355.76±54.9 μm and post injection BCVA at day 30 was 0.81±0.26
logMAR with CMT reducing to 292.20±40.81 μm, indicating statistical significance (P=0.001 and P<0.0001, respectively) for
all groups. Among the ocular side effects, none of the patients were reported with severe inflammation, endophthalmitis or rise
in intraocular pressure (IOP)>21 mm of Hg during follow up period of one month post injection. No systemic adverse events
were noted in study population.
Conclusion:
This retrospective analysis provides real time evidence regarding the efficacy and safety profile of bio-similar
of Bevacizumab, Zybev. However, more long term, prospective safety and efficacy studies are still awaited, this short term
retrospective data suggest that Zybev can be effective and safe in the management of ocular conditions including DME, wet
AMD and RVO.
sandx.pharma@gmail.comJ Clin Exp Ophthalmol 2018, Volume 9
DOI: 10.4172/2155-9570-C4-088